Piper Report
Blog on Medicare, Medicaid, pharma, biotech, health reform, and more. Insights and resources on hot issues. Kip Piper, editor.
Kip Piper, Editor
Health care strategist, speaker, and writer. Expert on Medicare, Medicaid, and pharma, biotech, and device industries. President, Health Results Group LLC. Senior Counselor, Fleishman-Hillard. Senior Consultant, Sellers Dorsey. Visit KipPiper.com. Or email Kip here.
Cartoon
Medicare Resources
Centers for Medicare & Medicaid Services
Federal Medicare Statutes (Title 18)
Medicare Advantage Enrollment
Medicare Advantage Rates
Medicare Advantage Rules
Medicare Drug Benefit Rules
Medicare Drug Plan Enrollment
Medicare Drug Plan Rates
Medicare Enrollment Data
Medicare Payment Advisory Commission
Medicare Rules (Part A, Part B)
Medicare Rules (Part B, Part C, Part D)
Special Needs Plans Data
Medicaid Resources
Center for Health Care Strategies
Federal Matching Rates (FMAP)
Federal Medicaid Rules (CMS)
Federal Medicaid Rules (CMS)
Federal Medicaid Statutes (Title 19)
National Association of State Medicaid Directors
Sellers Dorsey
State Coverage Initiatives
State Health Facts
State Medicaid Agencies
State Medicaid Expenditure Reports
Pharma & Biotech Resources
Biotechnology Industry Organization
Clinical Trials Database
FDA Advisory Committees on Biologics
FDA Advisory Committees on Drugs
FDA Approved Drugs
National Council for Prescription Drug Programs
Partnership for Prescription Assistance
Pharmacy Quality Alliance
PhRMA
Medical Device Resources
Advanced Medical Technology Association
FDA Advisory Committees on Devices
FDA Medical Device Database
Recently Approved Medical Devices
Health Reform Resources
Alliance for Health Reform
Center for Health Transformation
Center for Studying Health System Change
Health Innovations Exchange
Health Innovations Exchange
Sellers Dorsey
Health I.T. Resources
H.I.T. Clearinghouse
HHS Health Information Technology Office
National Association of Health Data Organizations
Quality & Safety Resources
Ambulatory Care Quality Alliance
Center for Health Transformation
Comparative Effectiveness Reviews
Healthcare Disclosure Project
Hospital Quality Alliance
Institute for Healthcare Improvement
Leapfrog Group
National Guideline Clearinghouse
National Quality Forum
National Quality Measures Clearinghouse
Pharmacy Quality Alliance
State Quality Improvement Institute
Legislative Resources
Congressional Budget Office
Congressional Research Service
Find Congressional Bills
Government Accountability Office
Health Legislation by Topic
House Energy and Commerce Committee
House Oversight Committee
House Ways and Means Committee
National Conference of State Legislatures
Senate Finance Committee
Senate Health, Education, Labor, and Pensions Committee
Regulatory Resources
FDA Regulations
Federal Medicaid Rules (CMS)
Federal Register
Medicare Advantage Rules
Medicare Drug Benefit Rules
Medicare Rules (Part A, Part B)
Medicare Rules (Part B, Part C, Part D)
Office of Management and Budget
Office of the Inspector General
Rules Under OMB Review
American Flag

Comparative Effectiveness and Safety: Emerging Methods and Tools to Compare Drugs, Devices, and Therapies
posted: October 9, 2007

Comparative%20Effectiveness%20Methods.jpgThe journal Medical Care has published series of outstanding articles on emerging methods and tools to compare the effectiveness of medical therapies, prescription drugs, and devices. The peer-reviewed articles are an outgrowth from a symposium on comparative effectiveness research sponsored by the Agency for Healthcare Research and Quality (AHRQ).


Here are links to the individual articles in PDF format:


  • Emerging Methods in Comparative Effectiveness and Safety: Symposium Overview and Summary.


  • Medicare Part D Data: Major Changes on the Horizon.


  • Methodologic Challenges to Studying Patient Safety and Comparative Effectiveness.


  • Creating and Synthesizing Evidence With Decision Makers in Mind: Integrating Evidence From Clinical Trials and Other Study Designs.


  • Improving Depiction of Benefits and Harms: Analyses of Studies of Well-Known Therapeutics and Review of High-Impact Medical Journals.


  • Cluster Randomized Trials: Opportunities and Barriers Identified by Leaders of Eight Health Plans.


  • Design of Cluster-Randomized Trials of Quality Improvement Interventions Aimed at Medical Care Providers.


  • Designed Delays Versus Rigorous Pragmatic Trials: Lower Carat Gold Standards Can Produce Relevant Drug Evaluations.


  • Practice-Based Evidence Study Design for Comparative Effectiveness Research.


  • Studying Prescription Drug Use and Outcomes With Medicaid Claims Data: Strengths, Limitations, and Strategies.


  • Assessment of Adherence to and Persistence on Disease-Modifying Antirheumatic Drugs (DMARDs) in Patients With Rheumatoid Arthritis.


  • Out-of-Pocket Pharmacy Expenditures for Veterans Under Medicare Part D.


  • Developing Indicators of Inpatient Adverse Drug Events Through Nonlinear Analysis Using Administrative Data.


  • Real-Time Vaccine Safety Surveillance for the Early Detection of Adverse Events.


  • Evaluation and Overview of the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance Project (NEISS-CADES).


  • Using Inverse Probability-Weighted Estimators in Comparative Effectiveness Analyses With Observational Databases.


  • A Simulation-Based Evaluation of Methods to Estimate the Impact of an Adverse Event on Hospital Length of Stay.


  • Evaluating the Validity of an Instrumental Variable Study of Neuroleptics: Can Between-Physician Differences in Prescribing Patterns Be Used to Estimate Treatment Effects?


  • Heterogeneity and the Interpretation of Treatment Effect Estimates From Risk Adjustment and Instrumental Variable Methods: Surgery for Early-Stage Breast Cancer.


  • Increasing Levels of Restriction in Pharmacoepidemiologic Database Studies of Elderly and Comparison With Randomized Trial Results.


  • Use of Propensity Score Technique to Account for Exposure-Related Covariates: An Example and Lesson.


  • Using Propensity Scores Subclassification to Estimate Effects of Longitudinal Treatments: An Example Using a New Diabetes Medication.


  • Adjustments for Unmeasured Confounders in Pharmacoepidemiologic Database Studies Using External Information.


  • Comparison of Meta-Analytic Results of Indirect, Direct, and Combined Comparisons of Drugs for Chronic Insomnia in Adults: A Case Study.

    • e-mail this entry
    Email this entry to:


    Your email address:


    Message (optional):


    Consider This
    In ancient China, physicians were paid only when their patients were kept well and often not paid if the patient got sick. If a patient died, a special lantern was hung outside the doctor's house. Upon each death, another lantern was added. This is the first known use of the two most powerful drivers for health care performance - incentives and transparency.
    Our Staff
    Kevin 'Kip' Piper
    Kip Piper
    Editor (on a real good day)

    Watson the Dog
    Watson Piper
    Managing Editor
    Profile of Kip Piper

    Healthcare Consultant
    President of Health Results Group LLC. Senior counselor with Fleishman-Hillard, the top public relations and communications consultancy. Senior consultant with Sellers Dorsey, the leading Medicaid and health reform consultancy.

    Expertise
    Leading authority on Medicare, Medicaid, and pharmaceutical, biotechnology, and medical device industry issues. Policy, finance, coverage, reimbursement, health and drug benefits, marketing, business development, innovation, and public affairs.

    Strategic Advisor
    Advised Fortune 100 companies, pharma and biotech firms, medical device firms, top federal officials, governors, members of Congress, foundations, and foreign leaders. Skilled, creative business and policy strategist and problem solver.

    Speaker
    Popular speaker at health industry conferences. Topics include Medicare, pharma business issues, Medicaid reform, coverage and reimbursement, and health innovation. Keynotes, seminars, and briefings.

    Thought Leader
    Testified before Congressional committees, negotiated major legislation, led groundbreaking programs, and designed and implemented numerous health innovations.

    Blogger
    Editor of the Piper Report, a leading health care blog with thousands of regular readers. Medicare, Medicaid, pharma, biotech, and more. News, advice, solutions, and resources.

    Writer
    Upcoming books include Medicare and Medicaid from A to Z and MediStrategy: Medicare and Medicaid Business Strategies.

    Editor
    Business and policy editor of American Health & Drug Benefits, peer reviewed journal for decision makers in health plans, drug plans, PBMs, CMS, states, and large employers, with circulation of 30,000.

    Learn More
    To learn more, please visit Kip at www.kippiper.com.
    linked-in.gif
    Syndicate Piper Report
    AtomEnabled RSS feed